About
Summary
Indifferent Diagnosis: The Health of BioPharma in 2025 is your inside pass to an industry running at two speeds—record-breaking M&A on one end, widespread cash-burn triage on the other. Veteran strategist Frank Dolan unpacks why 40 % of public biotechs are months from insolvency while giants like Pfizer and Novartis spend billions on de-risked assets; how AI, CRISPR, and next-gen delivery tech are redrawing drug-discovery maps; and where regulatory, demographic, and private-equity cross-currents will push the market next. Packed with hard data, boardroom stories, and survival playbooks, this audiobook arms executives, investors, and scientists with the context—and contrarian edge—needed to navigate 2025’s most volatile sector.Book information
Genre
Business and Economics
